Skip to content Skip to menu

Transparency Working Group

In August 2012 Medicines Australia established a broad-based working group to develop measures and policies that will further enhance transparency of payments and other transfers of value between healthcare professionals and the pharmaceutical industry.

The primary purpose of any further transparency measures will be to enable health consumers to be better informed about the nature of payments and transfers of value between healthcare professionals and the industry in general, as well as such interactions with industry by their own healthcare professionals.

The Working Group has now completed its work. It has developed a model for introducing greater transparency about payments and transfers of value between companies and healthcare professionals. The model is informed by the Principles for Transparency, which the Working Group developed to guide its development of a model. The Principles for Transparency are here pdf_icon 110k

The Transparency Model is now being released for consultation and discussion with all interested stakeholders.

The Transparency Working Group members did not reach a consensus on every aspect of the model. It has not been endorsed or agreed upon by any of the Transparency Working Group members’ organisations. The model provides a basis for consultation and feedback as part of the Medicines Australia Code of Conduct Review.

The Consultation and Discussion Paper provides some further explanation of certain aspects of model, including where different options were discussed within the Transparency Working Group. It presents a brief description of different options and invites stakeholders to consider these and respond to them. The Transparency Model Consultation and Discussion Paper is available here pdf_icon 187k

The Code of Conduct Review will start in July 2013. There will be a call for submissions and Medicines Australia is planning forums where all stakeholders may come together and discuss the transparency model. All stakeholders are encouraged to start this discussion and debate within their organisations and memberships in readiness for contributing to the consultation forums, which will be announced in the near future.

Transparency Working Group Communiqués

The Working Group’s Communiqués about the outcomes from its meetings are available below:

The Terms of Reference for the Transparency Working Group are here:

Dr Harvey’s and Ms Marcus’ travel costs to attend the Transparency Working Group meetings were assisted by Medicines Australia as necessary.

  • For the first, third, fourth and sixth meetings, Dr Harvey received return economy airfares between Melbourne and Sydney costing Medicines Australia $324.70, $557.70 and $466.09.
  • For the second meeting, Ms Marcus received a single economy airfare between Melbourne and Adelaide costing Medicines Australia $215.00 and was paid a sitting fee of $200.
  • For the fourth meeting Ms Marcus received a return economy airfare between Adelaide and Sydney costing Medicines Australia $625.70, reimbursement for taxis and parking of $143.24 and a sitting fee of $400.
  • For the fifth meeting Ms Marcus received a return economy airfare between Adelaide and Melbourne costing Medicines Australia $505.70, reimbursement for taxis and parking of $185.80 and a sitting fee of $400.
  • For the sixth meeting Ms Marcus received a return economy airfare between Adelaide and Sydney costing Medicines Australia $665.70, reimbursement for taxis and parking of $251.67 and a sitting fee of $400.